Challenges and unanswered questions in STEMI management

Hellenic J Cardiol. 2019 Jul-Aug;60(4):211-215. doi: 10.1016/j.hjc.2019.01.001. Epub 2019 Jan 9.

Abstract

The management of ST-segment elevation myocardial infarction (STEMI) has evolved significantly over the last decades. STEMI treatment includes reperfusion therapy, ideally by primary percutaneous coronary intervention (pPCI), modern antithrombotic therapy and secondary prevention measures. Even though many areas in the management of STEMI are well studied and analyzed in the guidelines, there are still challenges and unanswered questions on how to improve outcomes. This review aims to offer an insight in areas that need to be explored.

Keywords: Antithrombotic treatment; Myocardial infarction; Primary PCI.

Publication types

  • Review

MeSH terms

  • Acute Coronary Syndrome / mortality
  • Aged
  • Aged, 80 and over
  • Cyclosporine / pharmacology
  • Cyclosporine / therapeutic use
  • Female
  • Humans
  • Hypothermia
  • Male
  • Middle Aged
  • Mitochondria, Heart / drug effects
  • Myocardial Reperfusion / methods*
  • Percutaneous Coronary Intervention / methods*
  • Platelet Membrane Glycoproteins / antagonists & inhibitors
  • Practice Guidelines as Topic
  • Purinergic P2Y Receptor Antagonists / therapeutic use
  • ST Elevation Myocardial Infarction / epidemiology
  • ST Elevation Myocardial Infarction / therapy*
  • Secondary Prevention / methods
  • Thrombolytic Therapy / methods*
  • Time Factors
  • Treatment Outcome
  • Vasodilator Agents / therapeutic use

Substances

  • Platelet Membrane Glycoproteins
  • Purinergic P2Y Receptor Antagonists
  • Vasodilator Agents
  • Cyclosporine